Literature DB >> 6819957

Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).

N Brock, J Pohl, J Stekar, W Scheef.   

Abstract

Mesna is a pharmacologically unremarkable, physiologically largely inert and almost totally non-toxic thio compound. It is rapidly eliminated renally and only slightly permeates into tissues. It has been shown experimentally that the bladder damage inducible in the rat by administration of oxazaphosphorine cytostatics can be successfully prevented by quite small doses of mesna. The detoxifying action of mesna is limited to the kidneys and the efferent urinary tract. The systemic effects of the oxazaphosphorines, however, remain unaffected. This applies particularly to the curative oncocidal efficacy of these compounds. It has also been shown experimentally that mesna does not affect the curative effects of other cytostatic drugs (doxorubicin, BCNU, methotrexate, vincristine). The efficacy of the cardiac glycoside proscillaridin is also not impaired by mesna.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6819957     DOI: 10.1016/0277-5379(82)90143-2

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  27 in total

1.  Carcinogenic effect of cisplatin (cis-diammine-dichloroplatinum (II), CDDP) in BD IX rats.

Authors:  S R Kempf; S Ivankovic
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

2.  Experimental toxicology of ASTA Z 7557 (INN mafosfamide).

Authors:  J Pohl; P Hilgard; W Jahn; H J Zechel
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

3.  Prevention of cyclophosphamide-induced urotoxicity by reduced glutathione and its effect on acute toxicity and antitumor activity of the alkylating agent.

Authors:  O Tofanetti; E Cavalletti; A Besati; G Pratesi; G Pezzoni; F Zunino
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Interaction between cisplatin and mesna in mice.

Authors:  R T Dorr; K Lagel
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

5.  Ifosfamide combination chemotherapy in advanced breast cancer.

Authors:  H Schmid; M Kaufmann; E M Grischke; G Bastert
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

7.  Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.

Authors:  M Fukuoka; S Negoro; N Masuda; K Furuse; M Kawahara; N Kodama; H Ikegami; S Nakamura; H Nishio; T Ohnoshi
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

8.  Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study.

Authors:  A D Elias; L J Ayash; J P Eder; C Wheeler; J Deary; L Weissman; M Hunt; J Critchlow; L Schnipper; E Frei
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

9.  Role of carnitine in cancer chemotherapy-induced multiple organ toxicity.

Authors:  Mohamed M Sayed-Ahmed
Journal:  Saudi Pharm J       Date:  2010-08-05       Impact factor: 4.330

10.  Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.

Authors:  N Brock
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.